Preclinical evaluation of a novel polyphosphazene surface modified stent.

[1]  S. Buccheri,et al.  Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality? , 2015, Journal of the American College of Cardiology.

[2]  R. Virmani,et al.  Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model. , 2015, JACC. Cardiovascular interventions.

[3]  R. Virmani,et al.  Thrombogenicity and Early Vascular Healing Response in Metallic Biodegradable Polymer-Based and Fully Bioabsorbable Drug-Eluting Stents , 2015, Circulation. Cardiovascular interventions.

[4]  Samin K. Sharma,et al.  Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.

[5]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  C. Varenhorst,et al.  Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. , 2014, Journal of the American College of Cardiology.

[7]  R. Virmani,et al.  Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans , 2014, Circulation.

[8]  P. Serruys,et al.  The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. , 2014, JACC. Cardiovascular interventions.

[9]  M. Mack,et al.  Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. , 2013, Journal of the American College of Cardiology.

[10]  R. Virmani,et al.  Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. , 2013, The Journal of invasive cardiology.

[11]  R. Virmani,et al.  Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. , 2013, JACC. Cardiovascular interventions.

[12]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[13]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[14]  G. Richardt,et al.  Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers' lesion treatment) registry. , 2011, Journal of interventional cardiology.

[15]  R. Latini,et al.  Multi-Link Vision stent vs. first-generation drug-eluting stents: systematic review and meta-analysis. , 2011, QJM : monthly journal of the Association of Physicians.

[16]  D. Capodanno,et al.  The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial , 2011 .

[17]  R. Virmani,et al.  Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. , 2010, Biomaterials.

[18]  R. Virmani,et al.  Comparison of Inflammatory Response After Implantation of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries , 2009, Circulation.

[19]  C. Bode,et al.  Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  Ulrike Stampfl,et al.  Reduction of Late In-Stent Stenosis in a Porcine Coronary Artery Model by Cobalt Chromium Stents with a Nanocoat of Polyphosphazene (Polyzene-F) , 2008, CardioVascular and Interventional Radiology.

[21]  I. Berger,et al.  Efficacy of a polyphosphazene nanocoat in reducing thrombogenicity, in-stent stenosis, and inflammatory response in porcine renal and iliac artery stents. , 2008, Journal of vascular and interventional radiology : JVIR.

[22]  Ju Han Kim,et al.  Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of in-stent restenosis. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[23]  Ulrike Stampfl,et al.  Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F Nanocoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model , 2008, CardioVascular and Interventional Radiology.

[24]  P. Libby,et al.  Mast cells promote atherosclerosis by releasing proinflammatory cytokines , 2007, Nature Medicine.

[25]  M. Grunze,et al.  The Efficacy of Nanoscale Poly[bis(trifluoroethoxy) phosphazene] (PTFEP) Coatings in Reducing Thrombogenicity and Late In-Stent Stenosis in a Porcine Coronary Artery Model , 2007, Investigative radiology.

[26]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[27]  Yong Woo Lee,et al.  Role of interleukin-4 in atherosclerosis , 2006, Archives of pharmacal research.

[28]  C. Mackay,et al.  Gene Profiling in Atherosclerosis Reveals a Key Role for Small Inducible Cytokines: Validation Using a Novel Monocyte Chemoattractant Protein Monoclonal Antibody , 2005, Circulation.

[29]  M. Grunze,et al.  A New Polymer Concept for Coating of Vascular Stents Using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to Reduce Thrombogenicity and Late In-Stent Stenosis , 2005, Investigative radiology.

[30]  R. Franke,et al.  Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. , 2005, Clinical hemorheology and microcirculation.

[31]  R. Virmani,et al.  Preclinical restenosis models and drug-eluting stents: still important, still much to learn. , 2004, Journal of the American College of Cardiology.

[32]  F. Cambien,et al.  Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. , 2003, The American journal of cardiology.

[33]  M. Eisenberg,et al.  Coated stents for the prevention of restenosis: Part I. , 2002, Circulation.

[34]  M. Tabrizian,et al.  Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model. , 2002, Biomaterials.

[35]  Renu Virmani,et al.  Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.

[36]  B. Bouchard,et al.  Platelets, leukocytes, and coagulation , 2001, Current opinion in hematology.

[37]  M. Bureau,et al.  Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.

[38]  A. Tedgui,et al.  Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[40]  Welle,et al.  Plasma Protein Adsorption and Platelet Adhesion on Poly , 1998, Journal of colloid and interface science.

[41]  L. Demer,et al.  Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. , 1996, The Journal of clinical investigation.

[42]  E. Edelman,et al.  Endovascular stent design dictates experimental restenosis and thrombosis. , 1995, Circulation.

[43]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.